TTTurgay Turan

Turgay Turan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Turgay Turan has a total of 78 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The Relationship Between Hand Grip Strength and Erectile Dysfunction

    by Turgay Turan, Ilkın Hamıdzada, Yunus Erol Bozkurt, Mammad Khalılov, Muhammed Enes Bulut, Özgür Arıkan, Özgür Efiloğlu, Asıf Yıldırım

    The purpose of this study is to investigate the relationship between hand grip strength (HGS) and erectile dysfunction (ED) in men over 40 years old. The study aims to determine if HGS can serve as an indicator of ED severity and associated health conditions. In this study, 301 male participants were assessed for ED and HGS using standardised protocols. Participants completed questionnaires assessing ED severity, comorbidities and depression, while HGS was measured using a dynamometer and the relationship of the data obtained was evaluated. Participants with erectile dysfunction ED had higher rates of alcohol and cigarette consumption, comorbidities, and depression, along with lower hand grip strength HGS compared to those without ED. Additionally, lower HGS was associated with more severe ED and a higher prevalence of comorbid conditions such as hypertension, diabetes, and coronary artery disease. Our study underscores the potential of hand grip strength HGS as an indicator of ED severity, especially in patients with multiple comorbidities. While causality cannot be established due to the cross-sectional design, the findings support the integration of HGS measurements into clinical practice to enhance ED management and highlight the role of physical fitness in sexual health.

  • Predictors of BCG Therapy Complications in Non-Muscle-Invasive Bladder Cancer: A Clavien-Dindo-Based Study

    by Turgay Turan, Ozgur Efiloglu, Ilkin Hamidzada, Javid Ahmadzada, Salih Polat, Asif Yildirim

    Background: Intravesical Bacillus Calmette-Guérin (BCG) therapy is the standard adjuvant treatment for non–muscle-invasive bladder cancer (NMIBC), particularly in patients with carcinoma in situ, following transurethral tumor resection. Despite its proven oncological benefits, BCG therapy may be associated with a wide range of local and systemic adverse events. This study aimed to evaluate the clinical significance of BCG-related complications across the full severity spectrum and to assess their impact on treatment continuation using the Clavien–Dindo classification system. Methods: This retrospective study included 694 patients with bladder cancer who received intravesical BCG therapy between 2004 and 2024. Ethical approval was obtained prior to data collection. Patient demographics, comorbidities, tumor characteristics, and treatment details were recorded. Freeze-dried BCG (12.5 mg) was administered intravesically according to induction and maintenance protocols. Adverse events occurring during therapy were systematically classified using the Clavien–Dindo system. The primary outcome was the occurrence of any BCG-related complication. The median follow-up duration was 34 months. Results: The study cohort comprised 580 men (83.6%) and 114 women (16.4%), with a mean age of 65.1 ± 7.5. Maintenance BCG therapy was administered to 295 patients (42.5%). A total of 122 patients (17.6%) experienced BCG-related complications, the majority of which were low-grade (Clavien–Dindo grade ≤2). Severe complications were rare. In multivariate logistic regression analysis, increasing age (odds ratio [OR]: 1.055; 95% confidence interval [CI]: 1.033–1.078; p < 0.001) and high tumor grade (OR: 2.473; 95% CI: 1.379–4.436; p = 0.002) were identified as independent predictors of complications. Conclusions: Intravesical BCG therapy is generally safe and well tolerated. However, advanced age and high tumor grade are associated with an increased risk of treatment-related adverse events. These findings highlight the importance of careful patient selection, close monitoring, and individualized management strategies, particularly in elderly patients undergoing BCG therapy.

  • Enzalutamide Therapy for Metastatic Prostate Cancer

    by Yunus Erol Bozkurt, Turgay Turan

    Enzalutamide (ENZ), a potent androgen receptor pathway inhibitor, gained FDA approval in 2012 for metastatic castration-resistant prostate cancer (mCRPC) post-docetaxel chemotherapy. It exhibits high affinity to the androgen receptor (AR), disrupting AR signaling crucial for prostate cancer growth. Notably, ENZ’s mechanism inhibits AR nuclear translocation and exerts apoptotic effects, distinct from older antiandrogens like bicalutamide. Clinical trials demonstrate ENZ’s efficacy across various stages of prostate cancer, from metastatic hormone-sensitive disease to non-metastatic CRPC, prolonging overall and radiographic progression-free survival. ENZ’s favorable outcomes in combination therapies highlight its role in advancing prostate cancer treatment paradigms.

  • Second Resection and New Methods of Tumor Visualization in Bladder Cancer

    by Yunus Erol Bozkurt, Turgay Turan

    The chapter delves into the necessity and outcomes of secondary resection following transurethral resection of bladder tumor (TURBT). Furthermore, the chapter highlights the importance of timing between primary and secondary resections and explores various factors affecting the accuracy and success of TURBT operation.Transitioning to innovative tumor visualization methods, the chapter introduces Photodynamic Diagnosis (PDD), Narrow Band Imaging (NBI), the IMAGE1 S™ imaging system, and nanoparticle-based techniques. Overall, this chapter serves as a comprehensive guide to both conventional and emerging approaches in bladder cancer treatment and diagnosis, offering valuable information for clinicians, researchers, and healthcare professionals.

  • Open Access

    The Relationship Between Lymphocyte Subtypes with Clinicopathological Features and Prognosis of Prostate Cancer in Patients Undergoing Radical Prostatectomy

    by Furkan Sendogan, Turgay Turan, Hayriye Erman, Yavuz Onur Danacioglu, Ferruh Kemal Isman, Ramazan Gokhan Atis, M. Selcuk Silay, Turhan Caskurlu, Asif Yildirim

    Objective: The immune system has an essential role in the development of cancer by showing both anti-tumor and pro-tumor activities. Understanding the immune func- tion of patients with malignancy is of clinical importance for the evaluation, treatment, and prognosis of the disease. We aimed to evaluate lymphocyte subtypes in peripheral blood samples of prostate cancer patients and their relationship with clinicopathologi- cal features and prognosis. Methods: One hundred thirty-seven patients who underwent open radical prosta- tectomy were included in our study. The percentages of CD3+T lymphocyte, CD19+ B lymphocyte, CD16/56 natural killer cells, CD4+ helper T lymphocyte, CD8+ cytotoxic T lymphocyte, and CD45 total lymphocyte were evaluated for each patient using the blood sample taken into a hemogram tube before surgery. Results: The pathological stage was T2 for 64 of the cases and T3 for 73. The mean follow-up period of the patients was 12.81 ± 6.20 months. The CD3+/CD4+ counts of the patients with pathological stage T2 were found to be statistically significantly higher than stage T3. There was a statistically significant negative correlation between the prostate-specific antigen levels and CD3+/CD4+ percentages of the patients. There was no statistical significance between the percentages of lymphocyte subtypes and the presence of surgical margin, biochemical recurrence, adjuvant therapy, and cancer upgrade. Conclusion: We consider that the increase in the pathological stage and prostate-spe- cific antigen value and the decrease in the number of CD4+ T lymphocyte subtypes may be prognostic markers in prostate cancer patients. Cite this article as: Sendogan F, Turan T, Erman H, et al. The relationship between lymphocyte subtypes with clinicopathological features and prognosis of prostate cancer in patients undergoing radical prostatectomy. Urol Res Pract. 2023;49(4):253-258.


  • Open Access

    The Impact of Histological Variants on Oncological Outcomes in Patients with Muscle Invasive Bladder Cancer Treated with Radical Cystectomy

    by Özgür Efiloğlu, Mehmet Çağlar Çakıcı, Gözde Kır, Ayberk İpLikçi, Turgay Turan, Gözde Ecem Cecikoğlu, Asıf Yıldırım

    Objective: Bladder cancer is a heterogeneous entity characterized by a wide range of different morphologies. The aim of this study was to investigate the prognostic effect of bladder tumor with variant histology that is treated with radical cystectomy on oncological outcomes. Methods: One hundred eighty-six patients who underwent radical cystectomy between September 2001 and June 2020 were included in the study. The patients were divided into 2 groups variant histology group (n = 54) and transitional cell cancer group (n = 132). Clinicopathologic data were compared between the two groups. Results: The groups were similar in terms of demographic characteristics. In the mul- tivariate analysis of cancer-specific survival in transitional cell cancer against variant histology, high-grade detection of primary transurethral bladder tumor pathology, cystectomy pT, cystectomy positive lymph node, and positive surgical margin in cys- tectomy were determined to be statistically significant. Diagnosis of pT2 and high grade of primary transurethral bladder tumor pathology, cystectomy ≥ pT3, cystec- tomy positive lymph node, and positive surgical margin in cystectomy were statis- tically significant in multivariate analysis of overall survival. Cancer-specific survival time was estimated at 65.1 ± 8.3 months for variant histology and 134.2 ± 10.4 months for transitional cell cancer (P=.004). The estimated overall survival time was 61.9 ± 8.0 months in variant histology and 119.0 ± 9.8 months in transitional cell cancer (P = .014). Conclusion: Pathological features and prognosis of bladder cancer with variant histol- ogies are worse than those of pure urothelial bladder cancer. Overall survival and can- cer-specific survival are shorter in bladder cancer with variant histology than in pure urothelial bladder cancer. Following the diagnosis of variant histology in transurethral bladder tumor, poor prognosis must be considered in the treatment plan. Cite this article as: Efiloğlu Ö, Çağlar Çakıcı M, Kır G, et al. The impact of histological variants on oncological outcomes in patients with muscle invasive bladder cancer treated with radical cystectomy. Urol Res Pract. 2023;49(4):246-252.


  • Open Access

    Comparison of Biparametric and Multiparametric Prostate Magnetic Resonance Imaging in Predicting Oncologic Outcomes After Radical Prostatectomy

    by Ozgur Efiloglu, Nesrin Gunduz, Ayberk Iplikci, Mahmut Bilal Dogan, Mehmet Caglar Cakici, Turgay Turan, Asif Yildirim

    This study aimed to evaluate the difference in predicting the pathological stage of retropubic radical prostatectomy (RRP) and biochemical recurrence (BCR) in patients with Prostate Imaging Reporting and Data System (PIRADS) scores of 3 and 4 on biparametric prostate magnetic resonance imaging (bpMRI) compared to patients who upgraded from PIRADS 3 to PIRADS 4 based on the contrast-enhanced PIRADS version 2.1. This study evaluated 107 patients who underwent RRP and had preoperative multiparametric prostate magnetic resonance imaging (mpMRI) and were followed regularly. Group 1 included 31 patients evaluated as PIRADS 3 in both bpMRI and mpMRI, group 2 included 31 patients evaluated as PIRADS 3 in bpMRI and PIRADS 4 in mpMRI, and group 3 included 45 patients evaluated as PIRADS 4 without contrast. Comparisons were made between groups 1 and 2 and between groups 2 and 3. No significant difference was found between the groups in terms of demographic data, preoperative or postoperative radiology, and pathology findings. Extraprostatic extension positivity and BCR were more common in group 2 compared to group 1 although not significant. Multivariate regression analysis was performed to determine the risk factors in predicting BCR, which revealed the positivity of seminal vesicle invasion and high pathological stage in the pathology report as significant factors. Prostate-specific antigen (PSA) and PSA density were higher in group 3 than in group 2, but without significance. This study revealed that mpMRI did not contribute in predicting BCR after RRP compared to bpMRI.


  • The effects of shock wave lithotripsy and retrograde intrarenal surgery on renal function

    by Turgay Turan, Ferruh Kemal Isman, Özgür Efiloğlu, Nevin Genc Kahraman, Furkan Şendoğan, Yavuz Onur Danacioğlu, Ramazan Gokhan Atis, Asif Yildirim

    Introduction: The aim of this study was to compare the early effects of shock wave lithotripsy (SWL) and retrograde intrarenal surgery (RIRS) on renal function using the cystatin C levels. Material and methods: Serum samples were taken from each of the patients preoperatively, on the first postoperative day, and on the 30th postoperative day in order to evaluate the renal damage. The cystatin C level was determined using a particle-enhanced turbid metric immunoassay with a clinical chemistry analyzer. Results: In the comparison between the preoperative and postoperative cystatin C levels on day 1, there was an increase in the SWL group (p = .001); however, the decrease in the RIRS group was statistically significant (p = .007). There were statistically significant differences in the cystatin C levels on the first postoperative day in both groups (p = .001). In the SWL group, there was a statistically significant increase between the preoperative and the 30th postoperative day cystatin C levels (p = .006), but no differences were found between these levels in the RIRS group or between the two groups (p = .255). Conclusions: RIRS may be the preferred procedure for patients who need more renal function protection when treating renal stones <2 cm


  • Open Access

    Aberrant SOCS3 Promoter Methylation as a Noninvasive Diagnostic Biomarker for Locally Advanced Prostate Cancer

    by Berna Tan, Turgay Turan, Burcu Yucel, Sedef Altundağ Kara, Seda Salman Yılmaz, Asif Yildirim

    The aim of this study was to investigate the promoter methylation status of Rasassociated domain family 1A (RASSF1A), O-6-methylguanine-DNA methyltransferase (MGMT), Phosphatase with tensin homology (PTEN) and Suppressor of cytokine signaling 3 (SOCS3) tumor suppressor genes and evaluate the clinical utility of these genes as noninvasive, blood-based epigenetic biomarkers for the diagnosis of Prostate Cancer (PCa). A total of 41 consecutive patients and 10 healthy control groups were enrolled in the study. Pyrosequencing was performed to analyze the methylation levels of the promoter regions of the four tumor suppressor genes in patients compared to healthy controls. The promoter methylation levels of RASSF1A, MGMT, PTEN and SOCS3 did not differ between the patient and control groups. However, SOCS3 promoter methylation level was significantly higher for patients having locally advanced PCa compared to those having localized PCa (p<0.05). Our results indicated that SOCS3 could be a useful, noninvasive blood-based epigenetic biomarker for the diagnosis of locally advanced PCa.


  • Role of serum and urine TGF-β1, MMP-9, TIMP-2, and NGF-β levels and serum NLR in predicting recurrence and progression risks in patients with primary non-muscle invasive bladder cancer

    by Özgür Efiloğlu, Banu İşbilen Başok, Turgay Turan, Tuncay Toprak, Bülent Erol, Turhan Çaşkurlu, Asıf Yıldırım

    Objective: The current study aimed to examine the correlation between serum and urine transforming growth factor beta 1 (TGF-β1), matrix metallopeptidase 9 (MMP-9), tissue inhibitor of metalloproteinase 2 (TIMP-2), and nerve growth factor beta (NGF-β) levels and serum neutrophil-to-lymphocyte ratio (NLR) as well as the recurrence and progression risks of non-muscle invasive bladder cancer (NMIBC). Material and methods: The current study included 89 individuals: n=47, patients with primary NMIBC (patient group) and n=42, healthy controls (control group). The TGF-β1, MMP-9, TIMP-2, and NGF-β levels in the blood and urine samples were assessed using an enzyme-linked immunosorbent assay. Moreover, the serum NLR was evaluated. For the statistical analysis, a generalized linear model was used to compare the groups. In the analysis, gender and use of cigarettes were used as the secondary factors, and age was included as the covariate in the generalized linear model set for the intergroup evaluations. Meanwhile, a logistic regression model was utilized to evaluate the impact of the biomarkers on the risk of recurrence and progression. Results: The serum NLR was higher in the patient group than in the control group (p=0.033). The patients with disease recurrence had higher body mass index and MMP-9 levels, but the results were not statistically significant. Moreover, the patients with a high NLR had a high risk of disease progression (odds ratio [OR]=13.046, 95% confidence interval [CI]=1.057–161.18, p=0.045), whereas the patients with a high serum TGF-β1 level (OR=0.972, 95% CI=0.945–0.999, p=0.047) had a low risk of disease progression. Conclusion: High NLR and low TGF-β1 values were associated with an increased risk of disease progression in patients with NMIBC. However, no relationships were found between TGF-β1, MMP-9, TIMP-2, and NGF-β values and the recurrence of NMIBC. Cite this article as: Efiloğlu Ö, İşbilen Başok B, Turan T, Toprak T, Erol B, Çaşkurlu T, et al. Role of serum and urine transforming growth factor beta 1, matrix metallopeptidase 9, tissue inhibitor of metalloproteinase 2, and nerve growth factor beta levels and serum neutrophil-to-lymphocyte ratio in predicting recurrence and progression risks in patients with primary non-muscle invasive bladder cancer. Turk J Urol 2020; 46(3): 206-12.